Русский
Clinical example of successful escalation of lipid-lowering therapy taking into account modern drug capabilities
DOI: https://dx.doi.org/10.18565/pharmateca.2025.1.64-70
N.V. Korneeva, N.N. Mislimova
1) Far Eastern State Medical University, Khabarovsk, Russia; 2) Sakhalin Regional Clinical Hospital, Yuzhno-Sakhalinsk, Russia
The emergence of new classes of modern lipid-lowering drugs in recent years and their availability allow doctors to achieve target of low-density lipoprotein (LDL) levels in patients with very high and extreme cardiovascular risk. This is achieved by correctly assessing the initial cardiovascular risk and timely escalation of lipid-lowering therapy. The demonstrated clinical example shows the logic of the doctor in making decisions on intensifying therapy, searching for possible options for achieving the target LDL level and the result of successfully achieving the goal. The discussion section discusses the issues of therapeutic/medical inertia and the factors that can be influenced to overcome it.
Keywords: medical inertia, inclisiran, alirocumab, low-density lipoproteins, lipid-lowering therapy, ezetimibe, statins, cholesterol
About the Autors
Natalia V. Korneeva, Dr. Sci. (Med.), Associate Professor, Head of the Department of Faculty and Outpatient Therapy with a Course in Endocrinology,
Far Eastern State Medical University, Khabarovsk, Russia; Gladkova1982@mail.ru, ORCID: https://orcid.org/0000-0001-9878-180X; eLibrary SPIN: 7817-7670 (corresponding author)
Natalia N. Mislimova, Cardiologist, Regional Vascular Center of the Department of Cardiology 2, Sakhalin Regional Clinical Hospital, Yuzhno-Sakhalinsk, Russia; natalisha1991@mail.ru, ORCID: https://orcid.org/0009-0001-6842-7735
Similar Articles
